General Information of Drug Transporter (DTP) (ID: DTYE3RN)

DTP Name Voltage-gated potassium channel Kv7.1 (KCNQ1)
Gene Name KCNQ1
UniProt ID
P51787 (KCNQ1_HUMAN)
VARIDT ID
DTD0513
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Synonyms
ATFB1; ATFB3; IKs producing slow voltage-gated potassium channel subunit alpha KvLQT1; JLNS1; KCNA8; KCNA9; KCNQ1; KQT-like 1; KVLQT1; Kv1.9; Kv7.1; LQT; LQT1; RWS; SQT2; Potassium voltage-gated channel subfamily KQT member 1; WRS; Voltage-gated potassium channel subunit Kv7.1
DTP Family Voltage-Gated Ion Channel (VIC) Superfamily ;
Tissue Specificity Abundantly expressed in heart, pancreas,prostate, kidney, small intestine and peripheral blood leukocytes.Less abundant in placenta, lung, spleen, colon, thymus, testis andovaries.
Sequence
MAAASSPPRAERKRWGWGRLPGARRGSAGLAKKCPFSLELAEGGPAGGALYAPIAPGAPG
PAPPASPAAPAAPPVASDLGPRPPVSLDPRVSIYSTRRPVLARTHVQGRVYNFLERPTGW
KCFVYHFAVFLIVLVCLIFSVLSTIEQYAALATGTLFWMEIVLVVFFGTEYVVRLWSAGC
RSKYVGLWGRLRFARKPISIIDLIVVVASMVVLCVGSKGQVFATSAIRGIRFLQILRMLH
VDRQGGTWRLLGSVVFIHRQELITTLYIGFLGLIFSSYFVYLAEKDAVNESGRVEFGSYA
DALWWGVVTVTTIGYGDKVPQTWVGKTIASCFSVFAISFFALPAGILGSGFALKVQQKQR
QKHFNRQIPAAASLIQTAWRCYAAENPDSSTWKIYIRKAPRSHTLLSPSPKPKKSVVVKK
KKFKLDKDNGVTPGEKMLTVPHITCDPPEERRLDHFSVDGYDSSVRKSPTLLEVSMPHFM
RTNSFAEDLDLEGETLLTPITHISQLREHHRATIKVIRRMQYFVAKKKFQQARKPYDVRD
VIEQYSQGHLNLMVRIKELQRRLDQSIGKPSLFISVSEKSKDRGSNTIGARLNRVEDKVT
QLDQRLALITDMLHQLLSLHGGSTPGSGGPPREGGAHITQPCGSGGSVDPELFLPSNTLP
TYEQLTVPRRGPDEGS
Function
This potassium transporter associates with KCNE beta subunits and Induces a voltage-dependent by rapidly activating and slowly deactivating potassium-selective outward current. Promotes also a delayed voltage activated potassium current showing outward rectification characteristic. During beta-adrenergic receptor stimulation participates in cardiac repolarization by associating with KCNE1 to form the I(Ks) cardiac potassium current that increases the amplitude and slows down the activation kinetics of outward potassium current I(Ks). Muscarinic agonist oxotremorine-M strongly suppresses KCNQ1/KCNE1 current. When associated with KCNE3, forms the potassium channel that is important for cyclic AMP-stimulated intestinal secretion of chloride ions. This interaction with KCNE3 is reduced by 17beta-estradiol, resulting in the reduction of currents. During conditions of increased substrate load, maintains the driving force for proximal tubular and intestinal sodium ions absorption, gastric acid secretion, and cAMP-induced jejunal chloride ions secretion. Allows the provision of potassium ions to the luminal membrane of the secretory canaliculus in the resting state as well as during stimulated acid secretion. When associated with KCNE2, forms a heterooligomer complex leading to currents with an apparently instantaneous activation, a rapid deactivation process and a linear current-voltage relationship and decreases the amplitude of the outward current. When associated with KCNE4, inhibits voltage-gated potassium channel activity. When associated with KCNE5, this complex only conducts current upon strong and continued depolarization. Also forms a heterotetramer with KCNQ5; has a voltage-gated potassium channel activity.
Endogenous Substrate(s) Potassium ions
TCDB ID
1.A.1.15.6
Gene ID
3784
KEGG Pathway
Adrenergic signaling in cardiomyocytes (hsa04261 )
Cholinergic synapse (hsa04725 )
Gastric acid secretion (hsa04971 )
Pancreatic secretion (hsa04972 )
Protein digestion and absorption (hsa04974 )
Vibrio cholerae infection (hsa05110 )
Reactome Pathway
Phase 3 - rapid repolarisation (R-HSA-5576890 )
Phase 2 - plateau phase (R-HSA-5576893 )
Voltage gated Potassium channels (R-HSA-1296072 )

The Drug Therapeutic Target (DTT) Role of This DTP

DTP DTT Name Voltage-gated potassium channel Kv7.1 (KCNQ1) DTT Info
DTP DTT Type Successful
1 Approved Drug(s) Targeting This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indapamide DMGN1PW Edema MG29 Approved [1]
------------------------------------------------------------------------------------
1 Discontinued Drug(s) Targeting This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-768673 DMZ402C N. A. N. A. Terminated [2]
------------------------------------------------------------------------------------
13 Investigative Drug(s) Targeting This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
(3R,4S)-293B DM47BEG Discovery agent N.A. Investigative [3]
3S,4R-293B DMVGDSM Discovery agent N.A. Investigative [3]
HMR-1556 DMXMTA9 Discovery agent N.A. Investigative [4]
IKs124 DMLY5IF Discovery agent N.A. Investigative [5]
L-735,821 DMY60MG Discovery agent N.A. Investigative [6]
ML277 DMQ98RS Discovery agent N.A. Investigative [7]
N-(2-Diethylamino-ethyl)-4-hexyloxy-benzamide DMZ4A2X Discovery agent N.A. Investigative [8]
N-(3,3-Dimethyl-butyl)-4-hexyloxy-benzamide DM2Y5AP Discovery agent N.A. Investigative [8]
N-(3,3-Dimethyl-butyl)-4-indol-1-yl-benzamide DMEUXOQ Discovery agent N.A. Investigative [8]
N-(3,3-Dimethyl-cyclopentyl)-4-hexyloxy-benzamide DM6EJQ4 Discovery agent N.A. Investigative [8]
R-L3 DMGEDQJ Discovery agent N.A. Investigative [9]
XE991 DMLH1PK Discovery agent N.A. Investigative [10]
zinc pyrithione DMF0CRA Discovery agent N.A. Investigative [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 Investigative Drug(s)

References

1 Indapamide induces apoptosis of GH3 pituitary cells independently of its inhibition of voltage-dependent K+ currents. Eur J Pharmacol. 2006 Apr 24;536(1-2):78-84.
2 Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(... J Med Chem. 1997 Nov 21;40(24):3865-8.
3 A kinetic study on the stereospecific inhibition of KCNQ1 and I(Ks) by the chromanol 293B. Br J Pharmacol. 2001 Dec;134(8):1647-54.
4 Selective optimization of side activities: another way for drug discovery. J Med Chem. 2004 Mar 11;47(6):1303-14.
5 Heteromeric KCNE2/KCNQ1 potassium channels in the luminal membrane of gastric parietal cells. J Physiol. 2004 Dec 1;561(Pt 2):547-57.
6 Molecular determinants of KCNQ1 channel block by a benzodiazepine. Mol Pharmacol. 2003 Jul;64(1):70-7.
7 Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5936-41.
8 Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable I(Ks) blockers. J Med Chem. 2001 Nov 8;44(23):3764-7.
9 A novel benzodiazepine that activates cardiac slow delayed rectifier K+ currents. Mol Pharmacol. 1998 Jul;54(1):220-30.
10 Molecular basis for differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer XE991. Mol Pharmacol. 2000 Jun;57(6):1218-23.
11 Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol. 2007 May;3(5):287-96.